Silexion Therapeutics Corp. announced a reverse share split to preserve its Nasdaq listing, focusing on RNAi therapies for KRAS-driven cancers.
2 reports, 2 independent
Updated May 26
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Silexion Therapeutics Corp. announced a reverse share split to preserve its Nasdaq listing, focusing on RNAi therapies for KRAS-driven cancers.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Silexion Therapeutics Corp. pioneers RNAi therapies for KRAS-driven cancers, establishing partnerships with AMS and Catalent.Sub-event
Silexion Therapeutics Corp. executed a reverse share split to maintain its Nasdaq listing.1 source
Keep exploring
The entities involved
-
Nasdaq
American fully electronic stock exchange
Related events
- Valion Bio, Inc. is seeking a reverse stock split to maintain its listing on the Nasdaq stock exchange.
- Argenex SE and Capricor Therapeutics were listed on the Nasdaq stock exchange and are competing in the biotech sector.
- uniQure N.V. traded on the Nasdaq stock exchange and submitted a Biologics License Application (BLA) for accelerated approval of its gene therapy.
- C3is Inc. announced a reverse stock split to maintain its listing requirements on the Nasdaq stock exchange.
- The board of directors approved a proposed reverse stock split for a company seeking to maintain its listing on Nasdaq.
Coverage
Newest first; wire copies grouped- manilatimes.net
- GlobeNewswireSilexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation New Results Reveal Unprec